Literature DB >> 16076283

Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease.

Wendy M Miller1, Katherine E Nori Janosz, Jose Yanez, Peter A McCullough.   

Abstract

Obesity is currently an epidemic, and the prevalence of cardiovascular risk factors is increasing dramatically as a result. Visceral adiposity is correlated with a proinflammatory and prothrombotic state that is believed to promote atherosclerosis and acute coronary syndromes. This article will review clinical trials on the effects of weight loss and pharmacotherapy on obesity associated inflammatory and thrombotic markers linked with cardiovascular disease.

Entities:  

Mesh:

Year:  2005        PMID: 16076283     DOI: 10.1586/14779072.3.4.743

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  2 in total

Review 1.  Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target?

Authors:  Peter A McCullough
Journal:  Curr Atheroscler Rep       Date:  2009-09       Impact factor: 5.113

Review 2.  Adiposopathy is a more rational treatment target for metabolic disease than obesity alone.

Authors:  Harold Bays; Carlos A Dujovne
Journal:  Curr Atheroscler Rep       Date:  2006-03       Impact factor: 5.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.